

CERTIFICATE

Survey of 16 May 2025

You have fulfilled the requirements of the External Quality Assessment with the following analysis

Haemostasis 23 - Rivaroxaban (503):

Validity 12 months:

Rivaroxaban

(R) analysis is subject to the RiliBÄK

Customer:
10012430
MUDr. Martin Spacek, PhD.
Vseobecná fakultní nemocnice v Praze
Centrální hematologické laboratoře ULBLD
U Nemocnice 2
12808 Praha 2

Düsseldorf, 04 July 2025



Prof. Dr. med. Michael Spannagl
(Head of Reference Institution)



Prof. Dr. med. Dirk Peetz
(Adviser)

CERTIFICATE OF PARTICIPATION

Survey of 16 May 2025

You have participated in the External Quality Assessment with the following analysis

Haemostasis 23 - Rivaroxaban (503):

Rivaroxaban

(R) analysis is subject to the RiliBÄK

Customer:
10012430
MUDr. Martin Spacek, PhD.
Vseobecná fakultní nemocnice v Praze
Centrální hematologické laboratoře ULBLD
U Nemocnice 2
12808 Praha 2

Düsseldorf, 04 July 2025



Prof. Dr. med. Michael Spannagl
(Head of Reference Institution)



Prof. Dr. med. Dirk Peetz
(Adviser)